Home > Newsletters > FDAnews Drug Daily Bulletin > Controversy Around Canadian Province’s Choice of Stop-Smoking Drug
FDAnews Drug Daily Bulletin
May 15, 2012 | Vol. 9 No. 96
Controversy Around Canadian Province’s Choice of Stop-Smoking Drug
As the British Columbia government touts the popularity of its new smoking cessation program, which provides the stop-smoking pill Champix at no charge, a hearing to certify a class-action lawsuit against the drug’s manufacturer is set for the end of this month. Colwood’s Patricia Clow launched the class-action lawsuit in B.C. against Pfizer Canada and Pfizer Inc. two years ago.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.